Scientists, physicians, clinicians, healthcare practitioners, and pharmaceutical firms all over the world are competing against time to produce a COVID-19 vaccine when infections reach 14 million. Though progress is still a long way off, Oxford-AstraZeneca is one of the few that is nearing a breakthrough.
Serum Institute of India Pvt, which recently received DGCI permission to launch its indigenously produced pneumococcal vaccine, has joined hands with AstraZeneca to contribute to the development of the future vaccine candidate ChAdOx1 nCoV-19 for COVID-19.
The University of Oxford will soon have a milestone in the development of the COVID-19 vaccine as per studies. Oxford University researchers said the team has found after early-stage clinical trials that the jab will offer “double protection” against coronavirus.
However human tests have shown that the dosage of the proposed vaccine has resulted in developing both antibodies and killer T-cells in the body of the patient, they added. They said the findings were convincing; some experiments have shown that antibodies that disappear within months while T-cells remain in circulation for years to come.
The applicant for the vaccine from Oxford-AstraZeneca reached Phase III clinical trials. The Phase 1 trial yielded very positive results. The full details will be released by Oxford on 20 July 2020.
“It will be a long time before anyone receives a vaccine due to the number of doses to be given, “Serum Institute CEO Adar Poonawalla said in an interview, as reported by the Indian Express. He said the first approved vaccine could not be the right one.
“There are multiple research approaches to producing the COVID-19 vaccine, and we will have to wait to see which vaccine is best offered to the world,” Poonawalla said in an interview. He also added that it became one of the leading candidates for the COVID-19 vaccine. So, because they believe in the AstraZeneca vaccine, Serum has “engaged hundreds of millions of dollars” to its production.
Poonawalla said he expects a two-three-day release. “We will wait for that and then report on the Phase 1 trials they’ve completed,” he said. They are expecting to make millions of doses in the next three months until they get the license to manufacture and has also invested hundreds of millions of dollars to continue the manufacturing of the vaccine in Capex and Opex.